Busey Bank Lowers Stake in Danaher Corporation $DHR

Key Points

• Busey Bank has reduced its holdings in Danaher Corporation by 1.8%, now owning 98,194 shares valued at approximately $19.4 million.
• Recent earnings showed Danaher reporting $1.80 earnings per share, exceeding estimates and indicating a 3.4% revenue increase year-on-year.
• The company has declared a quarterly dividend of $0.32 per share, with a dividend yield of 0.7%, to be paid on October 31st.

Busey Bank cut its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,194 shares of the conglomerate's stock after selling 1,825 shares during the period. Busey Bank's holdings in Danaher were worth $19,397,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Nuveen LLC bought a new position in shares of Danaher in the 1st quarter valued at about $833,941,000. GAMMA Investing LLC lifted its stake in Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Invesco Ltd. lifted its stake in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its stake in Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Danaher in the fourth quarter worth about $242,837,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

NYSE DHR traded down $2.99 during trading hours on Monday, hitting $190.30. 2,949,617 shares of the company's stock traded hands, compared to its average volume of 4,145,042. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a market capitalization of $136.26 billion, a PE ratio of 40.49, a PEG ratio of 2.70 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm's 50-day moving average is $200.17 and its 200-day moving average is $198.18.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The business's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is 27.23%.

Analysts Set New Price Targets

DHR has been the subject of several analyst reports. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research report on Friday, July 11th. Evercore ISI reduced their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.